The relationship between paraoxonase, arylesterase, lipoprotein (a) and other lipid parameters in patients with coronary heart disease

Mehmet Özdin; Mehmet Ferit Gürsu

doi:10.7197/cmj.vi.766384

Research Article

Koroner kalp hastalarında paraoksonaz, arilesteraz, lipoprotein (a) ve diğer lipit parametreleri arasındaki ilişki

Year 2020, , 271 - 276, 27.10.2020

Mehmet Özdin , Mehmet Ferit Gürsu

https://doi.org/10.7197/cmj.vi.766384

Abstract

Amaç: Koroner Kalp Hastalığı (KKH) nedeni ile endüstrileşmiş ülkelerde her yıl milyonlarca kişi ölmekte, mortalite
nedenleri arasında ilk sırada yer almaktadır. KKH'nın nedenlerinin bilinmesi, erken tanı yöntemlerinin belirlenmesi
hayati önem taşımaktadır. High Density Lipoprotein (HDL) yapısında bulunan, Low Density Lipoprotein (LDL) oksidasyonunu önleyen ve antioksidan bir enzim olan paraoksonaz (PONl) aktivitesinin düşük olması KKH için bir risk

faktörüdür. KKH tanısı alan ve etiyolojik risk faktörleri taşıyan bireylerde serum PONl, arilesteraz (ARE) ve
Lipoprotein(a) (Lp(a)) düzeyleri ile diğer lipit bileşenleri arasındaki ilişkinin araştırılması amaçlandı.
Yöntem: Bu amaçla Fırat Üniversitesi Tıp Fakültesi Hastanesi Kardiyoloji kliniğine başvuran 80 KKH tanısı
alan hastanın serum PONl aktiviteleri, ARE aktiviteleri, Lp(a), apo A, apo B ve diğer lipid parametreleri
araştırıldı. KKH’ları; kardiyoloji polikliniğine gelen miyokard infarktüsü geçirmiş veya koroner anjiografi
sonucunda by-pass operasyonuna karar verilmiş, antiiskemik ilaç kullanan, diabeti olmayan, alkol ve sigara
içmeyen, aile hikayesinde koroner kalp hastalığı olmayan, lipit düşürücü ilaç almayan koroner kalp
hastalarından oluşmaktadır. Kontrol grubu kardiyovasküler hastalığı, diyabeti veya serum lipid düzeyini
etkileyen bir hastalığı olmayan sağlıklı 40 bireyden oluşmaktadır.
Bulgular: KKH'larında kolesterol, trigliserid (TG), HDL, LDL, VLDL, serum PONl ve ARE aktiviteleri, Lp(a), apo A
ve apo B düzeyleri sağlıklı kontrol grubu ile karşılaştırıldığında istatistiksel olarak anlamlı bulundu (p<0.05). Serum
PONl aktivitesi ve ARE aktivitesi hasta gruplarında sağlıklı kontrol grubuna oranla düşük, serum Lp(a) düzeyleri ise
yüksek bulunmuştur (p<0.05).
Sonuç: KKH tanısında önemli parametreler olarak kabul edilen serum PONI aktivitesi serum Lp(a) düzeyleri
çalışmamızda da anlamlı biyokimyasal belirteçler olarak saptanmıştır.

Keywords

Koroner kalp hastalığı, paraoksonaz, lipoprotein(a)

Supporting Institution

Fırat Üniversitesi Araştırma Fonu (FÜNAF-514)

Project Number

FÜNAF-514

References

1. Özkan S, Yılmaz ÖÇ. The relationship between metabolic syndrome score and cardiac ischemia detected by noninvasive cardiac tests. Cumhuriyet Medical Journal. 2020; 42(1): 44-48.
2. Martinez LG, Bucher L. Coronary Artery Disease and Acute Coronary Syndrome, Medical Surgical Nursing, Discover Books, USA. 2005; 784-785.
3. Badır A, Korkmaz FD. Koroner Arter Hastalıkları, Dahili ve Cerrahi Hastalıklarda Bakım, Üçüncü Baskı, İstanbul, Akademisyen Kitapevi. 2014; 431-445.
4. ESC Klavuzları, Avrupa Klinik Uygulamada Kardiyovasküler Hastalıklardan Korunma Klavuzu.Türk Kardiyoloji Derneği Arşivi. 2012; 40: 126-128.
5. Montalestcot G. ESC Kararlı Koroner Arter Hastalığı Yönetimi Kılavuzu. Türk Kardiyoloji Derneği Araştırma. 2014; 6: 96-100.
6. Forrester JS, Merz NB, Bush L. Task force fourth efficacy of risk factor management. JACC. 1996; 27: 991-1006.
7. Hamm WC. Israrcı ST Segment Yükselmesi Belirtileri Göstermeyen Hastalarda Akut Koroner Sendromların Tedavi Kılavuzları. Türk Kardiyoloji Derneği Arşivi. 2011; 39(3): 73-128.
8. World Health Organisation (WHO). The 10 leading causes of death in the world, 2000-2012, http:// www.who.int/ mediacentre/ factssheets/ fs310/en/, [10.10.2017]
9. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular Disease in Europe : Epidemiological Update, European Heart Journal. 2015; 37: 3232-3245.
10. Türkiye İstatistik Kurumu, Ölüm Nedeni İstatistikleri, 2014. www.tuik.gov.tr. Pre Haber Bültenleri, [10.10.2017]
11. Onat A, Karakoyun S, Akbaş T, Özpamuk KF, Karadeniz Y, Çakır H. TEKHARF 2014 taraması ve Türkiye’de coğrafi bölgelere göre ölüm oranı ile koroner hastalık insidansı: Türk Kardiyoloji Derneği Arşivi. 2015; 43(4): 326-332.
12. Özkan AA. Akut koroner sendromlar: Epidemiyoloj Türk Kardiyoloji Derneği Arşivi. 2013; (43)1: 1-3.
13. Günay GK, Bayrak TA, Özdin M. The Relationship of Lipo (a) and Paraoxonase with Diabetes Mellitus. GETATDER. 2019; 1(2): 5-8.
14. Gürsu MF, Özdin M. Sigara İçenlerde Serum Paraoksonaz (PON1) Aktiviteleri ile Malondialdehit Düzeylerinin Araştırılması. Fırat Tıp Dergisi. 2002; 7(2): 732-737.
15. Nevres KOYLAN. Lipoprotein(a) ve Ateroskleroz. Türk Kardiyol Dern Arş. 1999; 27: 483-490.
16. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ. Paraoxonase and coronaryheart disease. Curr Opin Lipid. 1998; 9(4): 319-324.
17. Yildiz A, Sezen Y, Gur M, Yilmaz R, Demirbag R, Erel O. Association of paraoxonase activity and coronary collateral flow. Coron Artery Dis. 2008; 19(7): 441-7.
18. Cagirci G, Cay S, Karakurt O, Yazihan N, Aydin C, Acikel S. Association between paraoxonase activity and late saphenous vein graft occlusion in patients with coronary artery bypass grafting. Kardiol Pol. 2009; 67(10): 1063-8.
19. Nair SP, Shah NC, Taggarsi A, Nayak U. PONI and its association with oxidative stress in type I and type II diabetes mellitus. Diabetes Metab Syndr. 2011; 5: 126-129.
20.Amine K, Atouk A, Moussamih S. Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients. Ann Biol Clin. 2011; 69: 671-617.
21. Petersdorf RG, Adams RD, Braimwald E, Isselbacher KJ, Martin JB, Wılson JD. Harrison's principals of intemal medicine. 3. Baskı, Mc Graw-Hill Co, USA. 1995: 661-669.
22. Brown MS, Golstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330: 111-114.
23. Marcovina SM, Koschinsky ML. Lipoprotein (a): structure, measurement, and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, (eds). Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997: 283-313.
24. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res. 1997; 27: 14-23.
25. Dangas G, Mehran R. Harpel PC, Sharma SK, Dube G, Marcovina SM. Lipoprotein (a) and inflamation in human coronary atheroma; association with the severity of clinical presentation. J Am Coll Cariol. 1998; 32: 2035-2042.
26. Aono H, Ito M, Ozawa H, Waki T, Magari Y, Bello MC, Rodoriguez. Lipoprotein (a) concentrations in healty subjects in the Dominic Republic.Comparison with Japenese. Jpn Heart J. 1999; 1: 65-70.
27. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD, Boerwinle E, Hobbs HH. Relation of plasma lipoprotein (a) to infarct artery patency in survivors of myocardial infarction. Circulation. 1993; 88: 935-940.
28. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serwn paraoxonase activity concentration and phenotype distribution in Diabetes Mellitus and its relationship serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995; 15: 1812-1818.
29. Çıkım G. Koroner kalp hastalarında dislipidemi ile yeni risk faktörlerinin karşılaştırılması. Uzmanlık Tezi, Elazığ: Fırat Üniversitesi Tıp Fakültesi, Biyokimya ve Klinik Biyokimya Bölümü, 2002.
30. Mackness MI, Mackness B, Durrington PN, Connely, PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Cur Opin Lipid. 1996; 7: 69-76.
31. Mackness Ml, Bouiller A, Hennuyer N, Mackness B, Hall M, Tailleux A. Paraoxonase activity is reduced by a proatherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000; 269: 232-236.
32. Mackness MI, Hallam S, Peart T, Wamers S, Walker CH. The seperation of sheep and human serum '' A'' esterase activity into the lipoprotein fraction by ultrasentrifugation. Comp Biochem Physiol B. 1985; 82(4): 675-677.
33. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH. Hill E. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype. Arterioscler Thromb Vasc Biol. 2001; 21: 1451-1457.
34. Ayup A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infiırction. Arterioscler Thromb Vasc Biol. 1999; 19: 330-335. (7) 74.
35. Mc Elveen J, Mackness MI, Colley CM., Peard T, Warner S, Walker CH. Distribution of Paraoxon Hidrolitic Activity in Serum of Patients After Myocardial lnfurction. Clin Chem. 1986; 32: 671-673.

The relationship between paraoxonase, arylesterase, lipoprotein (a) and other lipid parameters in patients with coronary heart disease

Year 2020, , 271 - 276, 27.10.2020

Mehmet Özdin , Mehmet Ferit Gürsu

https://doi.org/10.7197/cmj.vi.766384

Abstract

Objective: Millions of people die every year in industrialized countries due to coronary heart disease (CHD) and rank first among the causes of mortality. It is vital to know the causes of CHD and to determine early diagnosis methods. Low antioxidant enzyme paraoxonase (PONl) activity in High Density Lipoprotein (HDL) structure, which prevents Low Density Lipoprotein (LDL) oxidation, is a risk factor for CHD.

Method: For this purpose, serum PONl activities, ARE activities, Lp (a), apo A, apo B and other lipid parameters were investigated in 80 patients who were diagnosed with CHD who applied to the Cardiology Clinic of Fırat University Medical Faculty Hospital. CHD group; It consists of coronary heart patients who have undergone myocardial infarction to the cardiology outpatient clinic, or who have decided to by-pass operation as a result of coronary angiography, who use antiischemic drugs, have no diabetes, do not drink alcohol and smoke, do not have coronary heart disease in the family history, do not take lipid-lowering drugs. The control group consists of 40 healthy individuals without cardiovascular disease, diabetes or a disease affecting serum lipid level.

Results: Cholesterol, triglyceride (TG), HDL, LDL, VLDL, serum PONl and ARE activities, Lp (a), apo A and apo B levels were found statistically significant in the CHD compared to the healthy control group (p <0.05). Serum PONl activity and ARE activity were lower in the patient groups compared to the healthy control group, and serum Lp (a) levels were higher (p <0.05).

Conclusions: Serum PONI activity serum Lp (a) levels, which are accepted as important parameters in the diagnosis of CHD, were also found to be significant biochemical markers in our study.

Keywords

Coronary heart disease,, paraoxonase, lipoprotein(a).

Project Number

FÜNAF-514

References

1. Özkan S, Yılmaz ÖÇ. The relationship between metabolic syndrome score and cardiac ischemia detected by noninvasive cardiac tests. Cumhuriyet Medical Journal. 2020; 42(1): 44-48.
2. Martinez LG, Bucher L. Coronary Artery Disease and Acute Coronary Syndrome, Medical Surgical Nursing, Discover Books, USA. 2005; 784-785.
3. Badır A, Korkmaz FD. Koroner Arter Hastalıkları, Dahili ve Cerrahi Hastalıklarda Bakım, Üçüncü Baskı, İstanbul, Akademisyen Kitapevi. 2014; 431-445.
4. ESC Klavuzları, Avrupa Klinik Uygulamada Kardiyovasküler Hastalıklardan Korunma Klavuzu.Türk Kardiyoloji Derneği Arşivi. 2012; 40: 126-128.
5. Montalestcot G. ESC Kararlı Koroner Arter Hastalığı Yönetimi Kılavuzu. Türk Kardiyoloji Derneği Araştırma. 2014; 6: 96-100.
6. Forrester JS, Merz NB, Bush L. Task force fourth efficacy of risk factor management. JACC. 1996; 27: 991-1006.
7. Hamm WC. Israrcı ST Segment Yükselmesi Belirtileri Göstermeyen Hastalarda Akut Koroner Sendromların Tedavi Kılavuzları. Türk Kardiyoloji Derneği Arşivi. 2011; 39(3): 73-128.
8. World Health Organisation (WHO). The 10 leading causes of death in the world, 2000-2012, http:// www.who.int/ mediacentre/ factssheets/ fs310/en/, [10.10.2017]
9. Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular Disease in Europe : Epidemiological Update, European Heart Journal. 2015; 37: 3232-3245.
10. Türkiye İstatistik Kurumu, Ölüm Nedeni İstatistikleri, 2014. www.tuik.gov.tr. Pre Haber Bültenleri, [10.10.2017]
11. Onat A, Karakoyun S, Akbaş T, Özpamuk KF, Karadeniz Y, Çakır H. TEKHARF 2014 taraması ve Türkiye’de coğrafi bölgelere göre ölüm oranı ile koroner hastalık insidansı: Türk Kardiyoloji Derneği Arşivi. 2015; 43(4): 326-332.
12. Özkan AA. Akut koroner sendromlar: Epidemiyoloj Türk Kardiyoloji Derneği Arşivi. 2013; (43)1: 1-3.
13. Günay GK, Bayrak TA, Özdin M. The Relationship of Lipo (a) and Paraoxonase with Diabetes Mellitus. GETATDER. 2019; 1(2): 5-8.
14. Gürsu MF, Özdin M. Sigara İçenlerde Serum Paraoksonaz (PON1) Aktiviteleri ile Malondialdehit Düzeylerinin Araştırılması. Fırat Tıp Dergisi. 2002; 7(2): 732-737.
15. Nevres KOYLAN. Lipoprotein(a) ve Ateroskleroz. Türk Kardiyol Dern Arş. 1999; 27: 483-490.
16. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ. Paraoxonase and coronaryheart disease. Curr Opin Lipid. 1998; 9(4): 319-324.
17. Yildiz A, Sezen Y, Gur M, Yilmaz R, Demirbag R, Erel O. Association of paraoxonase activity and coronary collateral flow. Coron Artery Dis. 2008; 19(7): 441-7.
18. Cagirci G, Cay S, Karakurt O, Yazihan N, Aydin C, Acikel S. Association between paraoxonase activity and late saphenous vein graft occlusion in patients with coronary artery bypass grafting. Kardiol Pol. 2009; 67(10): 1063-8.
19. Nair SP, Shah NC, Taggarsi A, Nayak U. PONI and its association with oxidative stress in type I and type II diabetes mellitus. Diabetes Metab Syndr. 2011; 5: 126-129.
20.Amine K, Atouk A, Moussamih S. Paraoxonase-1 (PON1) activity in patients with coronary artery diseases and in diabetic patients. Ann Biol Clin. 2011; 69: 671-617.
21. Petersdorf RG, Adams RD, Braimwald E, Isselbacher KJ, Martin JB, Wılson JD. Harrison's principals of intemal medicine. 3. Baskı, Mc Graw-Hill Co, USA. 1995: 661-669.
22. Brown MS, Golstein JL. Plasma lipoproteins: teaching old dogmas new tricks. Nature 1987; 330: 111-114.
23. Marcovina SM, Koschinsky ML. Lipoprotein (a): structure, measurement, and clinical significance. In: Rifai N, Warnick GR, Dominiczak MH, (eds). Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997: 283-313.
24. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res. 1997; 27: 14-23.
25. Dangas G, Mehran R. Harpel PC, Sharma SK, Dube G, Marcovina SM. Lipoprotein (a) and inflamation in human coronary atheroma; association with the severity of clinical presentation. J Am Coll Cariol. 1998; 32: 2035-2042.
26. Aono H, Ito M, Ozawa H, Waki T, Magari Y, Bello MC, Rodoriguez. Lipoprotein (a) concentrations in healty subjects in the Dominic Republic.Comparison with Japenese. Jpn Heart J. 1999; 1: 65-70.
27. Moliterno DJ, Lange RA, Meidell RS, Willard JE, Leffert CC, Gerard RD, Boerwinle E, Hobbs HH. Relation of plasma lipoprotein (a) to infarct artery patency in survivors of myocardial infarction. Circulation. 1993; 88: 935-940.
28. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serwn paraoxonase activity concentration and phenotype distribution in Diabetes Mellitus and its relationship serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol. 1995; 15: 1812-1818.
29. Çıkım G. Koroner kalp hastalarında dislipidemi ile yeni risk faktörlerinin karşılaştırılması. Uzmanlık Tezi, Elazığ: Fırat Üniversitesi Tıp Fakültesi, Biyokimya ve Klinik Biyokimya Bölümü, 2002.
30. Mackness MI, Mackness B, Durrington PN, Connely, PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Cur Opin Lipid. 1996; 7: 69-76.
31. Mackness Ml, Bouiller A, Hennuyer N, Mackness B, Hall M, Tailleux A. Paraoxonase activity is reduced by a proatherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000; 269: 232-236.
32. Mackness MI, Hallam S, Peart T, Wamers S, Walker CH. The seperation of sheep and human serum '' A'' esterase activity into the lipoprotein fraction by ultrasentrifugation. Comp Biochem Physiol B. 1985; 82(4): 675-677.
33. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH. Hill E. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype. Arterioscler Thromb Vasc Biol. 2001; 21: 1451-1457.
34. Ayup A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infiırction. Arterioscler Thromb Vasc Biol. 1999; 19: 330-335. (7) 74.
35. Mc Elveen J, Mackness MI, Colley CM., Peard T, Warner S, Walker CH. Distribution of Paraoxon Hidrolitic Activity in Serum of Patients After Myocardial lnfurction. Clin Chem. 1986; 32: 671-673.

There are 35 citations in total.

Details

Primary Language	English
Subjects	Health Care Administration
Journal Section	Basic Science Research Articles
Authors	Mehmet Özdin 0000-0003-3077-7171 Mehmet Ferit Gürsu 0000-0003-3552-7315
Project Number	FÜNAF-514
Publication Date	October 27, 2020
Acceptance Date	September 21, 2020
Published in Issue	Year 2020

Cite

AMA	Özdin M, Gürsu MF. The relationship between paraoxonase, arylesterase, lipoprotein (a) and other lipid parameters in patients with coronary heart disease. CMJ. October 2020;42(3):271-276. doi:10.7197/cmj.vi.766384

Article Files

Full Text